Market Research Industry Reports

Sanofi (SAN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Summary

Sanofi is a healthcare company, which focuses on researching, developing, manufacturing and marketing of a wide range of medicines and vaccines. Its product portfolio includes medicines for the treatment of cancer, diabetes, rare diseases, multiple sclerosis and cardiovascular diseases; human vaccines for protection against various bacterial and viral diseases; and other products. The major products of the company include Aubagio, Lantus, Lovenox, Plavix and others. Sanofi also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; womens health; and vitamins, minerals and supplements. It has operations across Europe, the Americas, Asia-Pacific, Africa and the Middle East. Sanofi is headquartered in Paris, France.

Sanofi (SAN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 9
List of Figures 13
Sanofi, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 14
Sanofi, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 15
Sanofi, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 16
Sanofi, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 17
Sanofi, Medical Devices Deals, 2012 to YTD 2018 19
Sanofi, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 20
Sanofi, Pharmaceuticals & Healthcare, Deal Details 32
Asset Purchase 32
Sanofi Acquires Beacon OptoFluidic Platform from Berkeley Lights 32
Sanofi Acquires Consumer Healthcare Business of Boehringer Ingelheim 33
Genzyme Acquires Caprelsa from AstraZeneca 34
Sanofi Acquires Rights to Pediatric PRV from Retrophin for USD245 Million 35
Chattem Completes Acquisition Of Rolaids From McNEIL-PPC 36
Genzyme Completes Acquisition Of Leukine Manufacturing Facility From Bayer HealthCare For US$98.5 Million 37
Sanofi To Acquire Generic Drugs Rights From Medreich India 38
Venture Financing 39
Thermalin Raises Funds through First Tranche of Series A Preferred Financing 39
True North Therapeutics Raises USD45 Million in Series D Financing 40
True North Therapeutics Raises USD40 Million in Series C Financing 41
Portal Instruments Raises USD25 Million in Series B Financing 43
MyoKardia Raises USD46 Million in Series B Financing 44
True North Therapeutics Raises USD35 Million in Series B Financing 45
Portal Instruments Raises USD11 Million in Series A Venture Financing 46
True North Therapeutics Raises USD22 Million in Series A Venture Financing 47
Edimer Pharma Raises US$18 Million In Series B Financing 49
Ultragenyx Pharma Raises US$75 Million In Series B Financing 51
Kahr Medical To Raise US$2.5 Million In Venture Financing 53
Warp Drive Bio Raises US$75 Million In Series A Venture Financing 55
Private Equity 56
Advent International to Acquire Zentiva from Sanofi for USD2.37 Billion 56
Sanofi Plans to Sell Portfolio of Mature Drugs for USD8.6 Billion 58
Sanofi Plans to Sell Portfolio of Drugs 60
Partnerships 61
Evotec and APEIRON Biologics Enters into Licensing Agreement with Sanofi 61
Sanofi to Enter into R&D Agreement with Evotec 62
AnaBios and Sanofi Enter into Agreement 63
Iontas Enters into Agreement with Sanofi 64
Alnylam Pharma and Sanofi to Enter into Agreement 65
Sanofi to Form Partnership with Groupe Saidal and Pasteur Institute of Algeria 66
Berg Enters into Research Agreement with Sanofi 67
Applied BioMath Enters into Partnership with Sanofi 68
Sanofi Enters into Agreement with Max Delbruck Center, Charite and Berlin Institute of Health 69
Thermalin Enters into Partnership with Sanofi 70
Bioverativ Enters into Research Agreement with Bicycle Therapeutics 71
Axxam Enters into Research Agreement with Sanofi 72
AbCellera Biologics Enters into Partnership with Sanofi Pasteur 73
Ex Scientia Enters into Research and Option Agreement with Sanofi 74
Sanofi Enters into Research Agreement with Exscientia 75
Sanofi Enters into Co-Development Agreement with MedImmune 76
Sanofi Enters into Co-Promotion Agreement with Yakult Honsha 77
Enteris BioPharma Enters into Agreement with Sanofi 78
Sanofi Enters into Agreement with JHL Biotech 79
Natrix Separations Enters into Co-Development Agreement with Merck and Sanofi 80
Mymetics Enters into Research Agreement with Sanofi 81
Alnylam Pharma Enters into Agreement with Sanofi Genzyme 82
Myriad Enters into Agreement with Sanofi 83
Sanofi Pasteur Enters into Contract with US Department of Health and Human Services 84
Sanofi Pasteur Expands R&D Agreement with Walter Reed Army Institute of Research and Bio Manguinhos and Fiocruz 85
Sanofi Enters into Co-Development Agreement with Joslin Diabetes Center 86
Sanofi Enters into Research Agreement with Ksilink 87
Sanofi Genzyme Enters into Research Agreement with Johns Hopkins School of Medicine 88
Recursion Pharma Enters into Research Agreement with Genzyme 89
Hummingbird Bioscience Enters into Partnership with Sanofi 90
Sanofi Enters into Research Agreement with DiCE Molecules 91
Sanofi Enters into Drug Discovery Agreement with University of Tokyo 92
Sanofi and Juvenile Diabetes Research Foundation Partner with Four Research Organizations 93
Jubilant Biosys Enters into Agreement with Sanofi-Aventis Deutschland 95
X-Chem Enters into Agreement with Sanofi 96
Daiichi Sankyo, Japan Vaccine and Sanofi Enter into Co-Marketing Agreement 97
Sanofi Pasteur Enters into Partnership with Infectious Disease Research Institute 98
PeptiDream Enters into Discovery Agreement with Sanofi 99
Evotec Enters into Research Agreement with Sanofi 100
Regeneron Pharma Amends Co-Development Agreement with Sanofi 101
Sanofi-Aventis Extends Agreement with Medicines For Malaria Venture 103
Zhejiang Hisun Pharma Enters into Memorandum of Understanding (MoU) with Sanofi 104
Pendopharm Enters into Distribution Agreement with Sanofi-aventis Canada 105
NeuroVive Pharma Enters into Co-Development Agreement with Sanofi 106
Ablynx Enters into Research Agreement with Genzyme 107
Innate Pharma Enters into Agreement with Sanofi for Next Generation Antibody-Drug Conjugates 108
VBI Vaccines Enters into Research Agreement with Sanofi Pasteur 109
Schrodinger Enters into Agreement with Sanofi 110
Regeneron Pharma Amends Co-Development Agreement with Sanofi 111
Voyager Therapeutics Enters into Development Agreement with Genzyme 112
Adimab Enters into Agreement with Sanofi for Bispecific Antibody 113
Sanofi Enters into Research Agreement with Vect-Horus 114
Catalent Pharma Enters into Co-Development Agreement with Sanofi-Aventis 115
Evotec to Enter into Co-Development Agreement with Sanofi 116
Immune Design Enters into Co-Development Agreement with Sanofi Pasteur 118
Selecta Biosciences and Juvenile Diabetes Research Foundation Enter into Co-Development Agreement with Sanofi 119
Apollo Hospitals Plans to Form Joint Venture with Sanofi 120
Genzyme Enters into Co-Development Agreement with University of Florida and University of Pennsylvania 121
Charcot-Marie-Tooth Association Enters into Agreement with Genzyme to Discover Therapies for CMT1A 122
Sanofi Extends its Co-Development Agreement with MyoKardia 123
Sanofi Enters into Distribution Agreement with Emcure for Oncology Drugs 125
Sanofi Enters into Co-Development Agreement with Medtronic 126
Sanofi Enters into Drug Discovery Agreement with CQDM 127
Dubai Investments to Enter into Agreement with Sanofi to Promote Generics 128
Genzyme Enters Into Research Agreement With Cleveland Clinic 129
Sanofi Pasteur Enters Into Agreement With SK Chemicals For Pneumococcal Conjugate Vaccine 130
Sanofi Enters Into Agreement With UCB For Drug Discovery 131
Alnylam Pharma And Genzyme Enter Into Agreement For RNAi Therapeutics As Genetic Medicines 132
Smartox Biotech Enters Into Research Agreement With Sanofi For Drug Discovery 134
Regulus Therapeutics Expands Agreement With Sanofi 135
Sanofi Pasteur Enters into Agreement with University of Melbourne to Develop Human Vaccines 137
Alnylam Pharma And Genzyme Expands Co-Development Agreement For RNAi Therapeutics 138
Sanofi Pasteur Enters Into Agreement With Bill & Melinda Gates Foundation To Discover Vaccines 139
Gubra Enters into Research Collaboration with Sanofi 140
Institut Curie Enters Into Research Agreement With Sanofi To Develop Ovarian Cancer Treatments 141
NextBio Enters Into Agreement With Sanofi For Translational Medicine 142
Takeda Pharma Enters Into Co-Promotion Agreement With Sanofi For Alogliptin 143
Sanofi Pasteur Enters Into Co-Development Agreement With Xiamen University For Universal Flu Vaccine 144
Oncodesign Enters Into Research Agreement With Sanofi 145
Sanofi-Aventis Expands Co-Promotion Agreement with NovaMed Pharma 146
PharmAbcine Enters Into Research Agreement With Sanofi For Antibody Drug Discovery 147
Sutro Biopharma Enters Into Co-Development Agreement With Sanofi Pasteur 148
Y-Biologics Expands Agreement with Sanofi 149
Hanmi Pharma Enters Into Co-Marketing Agreement With Sanofi-Aventis For Ibestin 150
LG Life Sciences Enters Into Co-Promotion Agreement With Sanofi-Aventis Korea For Zemiglo 151
Sanofi Enters Into R&D Agreement With Massachusetts General Hospital For Translational Oncology Research 152
China State Institute of Pharma Enters Into Research Agreement With Sanofi 153
Sanofi Enters Into Research Agreement With Charite- Universitatsmedizin For Treatment Of Diabetes 154
Sanofi Enters Into Research Agreement With TB Alliance To Advance Treatments For Tuberculosis 155
Sanofi Enters Into Research Agreement With Oncodesign 156
LegoChem Biosciences Enters into Research Agreement with Sanofi 157
Sanofi Enters Into Research Agreement With Brigham and Womens Hospital 158
Regulus Therapeutics Expands Agreement With Sanofi-Aventis 159
Sanofi Forms Joint Venture With Hisamitsu Pharma For OTC Medications 160
Sanofi Enters Into Co-Development Agreement With Joslin Diabetes Center For Novel Diabetes Drugs 161
Sanofi Enters Into Research Agreement With Bioneer 162
Sanofi Enters Into Co-Development Agreement With Alfresa For Antiepileptic Drug 163
Sanofi Enters into Co-Development Agreement with CNRH, INRA, ASL and 3iNature 164
Centre For Genomic Regulation Enters Into Research Agreement With Sanofi 165
Centre de Regulacio Genomica Enters Into Research Agreement With Sanofi 166
Sanofi Pasteur India Enters Into Co-Marketing Agreement With Emcure Pharma For Rabies Vaccine 167
University of California Enters Into Research Agreement With Sanofi 168
Foundation Medicine Enters Into Co-Development Agreement With Sanofi For Genetic Biomarkers And Potential Diagnostics 169
Merger 170
Sanofi Japan and Genzyme Japan Merge 170
Licensing Agreements 171
Bioverativ Enters into Licensing Agreement with Oxford BioMedica 171
Sanofi Pasteur Enters into Licensing Agreement with SK Chemicals 172
Asahi Kasei Pharma Enters into Licensing Agreement with Sanofi 173
Sanofi to Enter into Licensing Agreement with Principia Biopharma 174
Sanofi Enters into Licensing Agreement with Ablynx 175
Sanofi Enters into Licensing Agreement with ImmuNext 176
Sanofi Enters into Licensing Agreement with Hanmi Pharma 177
IXALTIS Enters into Licensing Agreement with Sanofi 178
Mundipharma Enters into Licensing Agreement with SkyePharma and Sanofi for Flutiform 179
Sanofi Enters into Licensing Agreement with Innate Pharma 180
Sanofi Amends Licensing Agreement with Lexicon Pharma 181
Sanofi Enters into Licensing Agreement with Ligand Pharma 183
Zai Lab Enters into Licensing Agreement with Sanofi 184
Sanofi Enters into Licensing Agreement with Immune Design 185
CureVac Enters into Licensing Agreement with Sanofi Pasteur to Develop mRNA-Based Prophylactic Vaccine 186
Sanofi Enters into Licensing Agreement with Eli Lilly for Cialis 187
Oxford BioMedica Amends Licensing Agreement With Sanofi 189
Regulus Therapeutics Amends Licensing Agreement With Sanofi 190
Tolero Pharma Enters Into Licensing Agreement With Sanofi For Alvocidib 191
Chugai Pharma Expands Licensing Agreement with Kowa for DEBERZA 192
Sanofi Enters into Licensing Agreement with Bristol-Myers Squibb 193
Lumena Pharma Enters Into License Agreement With Sanofi For LUM002 194
Sanofi Pasteur Expands Licensing Agreement With Vivalis 195
Sanofi Enters into Licensing Agreement with Affilogic 196
Sanofi Enters into Licensing Agreement with Warp Drive Bio 197
Sanofi Enters into Licensing Agreement with MAB Discovery 198
Sanofi Enters into Licensing Agreement with BioNTech 199
Selecta Biosciences Exercises Option for Licensing Agreement with Sanofi 200
Sanofi Enters into Licensing Agreement with Lead Pharma for Autoimmune Diseases 201
ZAI Lab Enters into Licensing Agreement with Sanofi for Two Respiratory Drugs 202
Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Intra-Strand Base-Pairing Technology 203
Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Duplex Gene Therapy Vector Technology 204
Sanofi Pasteur Enters Into Licensing Agreement With ORGANOBALANCE For Saccharomyces Cerevisiae 205
Equity Offering 206
JHL Biotech Raises USD80 Million in Private Placement of Shares 206
Voyager Therapeutics Raises USD30 million in Private Placement of Series B Preferred Stock 207
Alnylam Pharma Raises USD70.7 Million in Private Placement of Shares 208
X4 Pharma Spin Off from Sanofi 210
Regulus Therapeutics Completes Private Placement Of Shares For US$10 Million 211
KaloBios Pharma Completes IPO For US$70 Million 212
Debt Offering 214
Sanofi Prices Third Tranche of Public Offering of 0.5% Notes Due 2023 for USD2.2 Billion 214
Sanofi Prices Second Tranche of Public Offering of Notes Due 2020 for USD0.6 Billion 215
Sanofi Prices Fourth Tranche of Public Offering of 1% Notes Due 2026 for USD1.9 Billion 216
Sanofi Prices Fifth Tranche of Public Offering of 1.375% Notes Due 2030 for USD2.47 Billion 217
Sanofi Prices Sixth Tranche of Public Offering of 1.875% Notes Due 2038 for USD1.6 Billion 218
Sanofi Prices First Tranche of Public Offering of Notes Due 2020 for USD1.2 Billion 219
Sanofi Prices Public Offering of Notes Due 2022 for USD948 Million 220
Sanofi Prices Public Offering of Notes Due 2027 for USD1.3 Billion 221
Sanofi Prices Public Offering of Notes Due 2020 for USD1.1 Billion 222
Sanofi Raises USD798.08 million in Public Offering of Notes Due 2028 223
Sanofi Raises USD684.07 million in Public Offering of Notes Due 2024 224
Sanofi Raises USD570 million in Public Offering of Notes Due 2019 225
Sanofi Prices Public Offering of Notes Due 2019 for USD850 Million 226
Sanofi Prices Public Offering of 1.5% Notes Due 2025 for USD850 Million 227
Sanofi Prices Public Offering of 0.875% Notes Due 2021 for USD566.4 Million 228
Sanofi Prices Public Offering of 1.75% Notes Due 2026 for USD1.64 Billion 229
Sanofi Prices Public Offering of 1.125% Notes Due 2022 for USD1.31 Billion 230
Sanofi Prices Public Offering of Floating Rate Notes Due 2018 for USD984 Million 231
Sanofi Prices Public Offering Of Bonds Due 2023 For US$1.35 Billion 232
Sanofi Prices Public Offering Of Bonds Due 2020 For US$1.3 Billion 233
Sanofi Completes Public Offering Of Notes Due 2018 For US$1.5 Billion 234
Sanofi Completes Public Offering Of Notes Due 2017 For US$960 Million 236
Asset Transactions 237
Partner Therapeutics Acquires Rights of Leukine from Sanofi 237
MicroPharm Acquires Equine Antivenom Immunoglobulin Products from Sanofi Pasteur 238
Emergent BioSolutions Acquires ACAM2000 Business from Sanofi 239
INTEGA Skin Sciences Acquires Alyria Skincare Product Line from Sanofi Consumer Health for USD1.3 Million 241
Ipsen Acquires Healthcare Portfolio from Sanofi for USD88.3 Million 242
Impact Biomedicines Acquires Rights for Fedratinib from Sanofi 244
Icagen Acquires Arizona Research Facility from Sanofi 245
Merus Labs Acquires French Rights to Four Products from Sanofi for USD25 Million 246
Validus Pharma and Wood Creek Capital Acquire US Rights to Several Product Lines from Sanofi-Aventis US 247
Moberg Pharma Acquires Balmex from Chattem for USD3.9 Million 248
Valeant Canada Acquires Canadian Rights from Sanofi-aventis for Altace and Altace HCT 249
Ferring Pharma Acquires Ddavp from Sanofi 250
Prollenium Medical Acquires Rights to Alyria Skincare Portfolio from Sanofi Consumer Health 251
Admedus Acquires Manufacturing Facility From Genzyme Australasia 252
Regeneron Pharma Acquires Rights To Two Antibodies From Sanofi 253
Covis Pharma To Acquire US Commercialization Rights For Five Products From sanofi-aventis 254
Wood Pharma To Acquire Production Facility In Hlohovec From Zentiva 256
Fareva Acquires API Production Site from Sanofi 257
Ubichem Pharma Services Acquires Manufacturing Facility In Hungary From Sanofi 258
Acquisition 259
Sanofi Acquires Bioverativ for USD11.5 Billion in Tender Offer 259
Zentiva to Acquire Additional 18.32% Stake in Sicomed for USD70.9 Million 261
Sanofi to Acquire Ablynx for USD4.85 Billion 262
Sanofi Acquires Protein Sciences 264
Bioverativ Therapeutics Acquires True North Therapeutics 265
Eurapharma Plans to Acquire 51% Stake in Maphar 266
Medis Labs Acquires Winthrop Pharma from Sanofi 267
Sanofi May Acquire Flexion Therapeutics for up to USD1 Billion 268
Sanofi May Acquire BioMarin Pharma 269
Sanofi to Sell 4.76% Stake in Nichi-iko Pharma 270
Sanofi May Acquire PTC Therapeutics 271
Sanofi-Synthelabo Acquires 20% Stake in Apollo Sugar Clinics for USD14.6 Million 272
Dubai Investments Divests 66% Stake in Globalpharma 273
Aastrom Biosciences Completes Acquisition of Genzyme Biosurgery from Sanofi for USD6.5 Million 274
Sanofi-Aventis To Acquire Minority Stake In Shantha Biotechnics For US$123 Million 275
LOreal Plans To Sell Its Stake In Sanofi 276
Sanofi Plans To Acquire Consumer Healthcare Products Company In China 277
Sanofi Completes Acquisition Of Genfar, Generic Drugs Manufacturer 278
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 279
Sanofi-Aventis Israel To Acquire Consumer Healthcare Products Company 281
Evotec Acquires DeveloGen For USD18 Million 282
Sanofi - Key Competitors 284
Sanofi - Key Employees 285
Sanofi - Locations And Subsidiaries 287
Head Office 287
Other Locations & Subsidiaries 287
Joint Venture 300
Recent Developments 302
Financial Announcements 302
Nov 02, 2017: Sanofi: Q3 2017 Business EPS up 1.1% at CER FY 2017 Guidance Confirmed 302
Jul 31, 2017: Sanofi Raises FY 2017 Business EPS Guidance to Broadly Stable at CER 309
Jul 12, 2017: Sanofi: Pre-quarterly Results Communication 315
Apr 28, 2017: Sanofi Delivers Robust Q1 2017 Financial Results 317
Feb 08, 2017: Sanofi Delivers 2016 Sales and Business EPS Growth at CER 323
Corporate Communications 331
Jan 19, 2018: Sanofi Appoints Dominique Carouge Executive Vice President Head of Business Transformation and Member of the Executive Committee 331
Apr 12, 2017: Sanofi appoints Nikhilesh Kalra to lead Consumer Healthcare business for India and South Asia 332
Apr 11, 2017: Sanofi Announces Pre-quarterly Results Communication 333
Feb 01, 2017: Sanofi Appoints Hugo Fry as General Manager UK 335
Government and Public Interest 336
Dec 05, 2017: Sanofi and IBM Watson Health real-world analysis showed that individuals not achieving control on basal insulin within 12 months 336
Sep 14, 2017: Insulin therapy initially declined and delayed by an average of 2 years 337
Product News 338
Dec 12, 2017: Striving to Defeat Dengue with Effective Vaccines 338
Dec 06, 2017: Sanofi continues to seek clinical trial waiver in India for controversial dengue vaccine 340
10/17/2017: Sanofi Genzyme Presents Abstracts on Lemtrada at ECTRIMS-ACTRIMS 341
09/20/2017: Sanofi and NIH researchers develop "three-in-one" antibodies as a potential breakthrough intervention for HIV/AIDS 343
09/11/2017: Sanofi Launches Combiflam ICYHOT Pain Relief Topical in India 344
06/16/2017: Shantha Biotechnicss Cholera Vaccine Completes Milestone of Delivering 10 Million Doses 345
Clinical Trials 346
Oct 27, 2017: Treatment Effects Maintained Over Five Years in Patients with Relapsing Remitting Multiple Sclerosis who Received Sanofi Genzymes Lemtrada (alemtuzumab) in Extension Study After Switching from Interferon Beta-1a 346
Apr 25, 2017: New Investigational Data on Six-Year Efficacy of Sanofi Genzymes Lemtrada (alemtuzumab) in Multiple Sclerosis Patients Who Experienced Relapse Between Treatment Courses To Be Presented at AAN 348
Feb 02, 2017: First Subjects Dosed in MyoKardia Phase 1 Study of Dilated Cardiomyopathy Candidate MYK-491 350
Jan 12, 2017: Protein Sciences Zika Vaccine Shows Good Results in Preclinical Testing 351
Other Significant Developments 352
Apr 12, 2018: Sanofi to invest 350 million in Canadian vaccine facility 352
Feb 27, 2018: Sanofi Adopts Genedata Selector to Optimize Strain Development 353
Feb 07, 2018: Sanofi Delivers 2017 Business EPS in line with Guidance 354
Mar 02, 2017: Sanofi Launches Digital Clinical Trials to Improve Recruitment and Reduce Trial Times 356
Jan 09, 2017: MannKind Receives $30.6 Million From Sanofi 357
Appendix 358
Methodology 358
About GlobalData 358
Contact Us 358
Disclaimer 358

List Of Tables

List of Tables
Sanofi, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Sanofi, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 14
Sanofi, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 15
Sanofi, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 16
Sanofi, Deals By Therapy Area, 2012 to YTD 2018 17
Sanofi, Medical Devices Deals, 2012 to YTD 2018 19
Sanofi, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 20
Sanofi Acquires Beacon OptoFluidic Platform from Berkeley Lights 32
Sanofi Acquires Consumer Healthcare Business of Boehringer Ingelheim 33
Genzyme Acquires Caprelsa from AstraZeneca 34
Sanofi Acquires Rights to Pediatric PRV from Retrophin for USD245 Million 35
Chattem Completes Acquisition Of Rolaids From McNEIL-PPC 36
Genzyme Completes Acquisition Of Leukine Manufacturing Facility From Bayer HealthCare For US$98.5 Million 37
Sanofi To Acquire Generic Drugs Rights From Medreich India 38
Thermalin Raises Funds through First Tranche of Series A Preferred Financing 39
True North Therapeutics Raises USD45 Million in Series D Financing 40
True North Therapeutics Raises USD40 Million in Series C Financing 41
Portal Instruments Raises USD25 Million in Series B Financing 43
MyoKardia Raises USD46 Million in Series B Financing 44
True North Therapeutics Raises USD35 Million in Series B Financing 45
Portal Instruments Raises USD11 Million in Series A Venture Financing 46
True North Therapeutics Raises USD22 Million in Series A Venture Financing 47
Edimer Pharma Raises US$18 Million In Series B Financing 49
Ultragenyx Pharma Raises US$75 Million In Series B Financing 51
Kahr Medical To Raise US$2.5 Million In Venture Financing 53
Warp Drive Bio Raises US$75 Million In Series A Venture Financing 55
Advent International to Acquire Zentiva from Sanofi for USD2.37 Billion 56
Sanofi Plans to Sell Portfolio of Mature Drugs for USD8.6 Billion 58
Sanofi Plans to Sell Portfolio of Drugs 60
Evotec and APEIRON Biologics Enters into Licensing Agreement with Sanofi 61
Sanofi to Enter into R&D Agreement with Evotec 62
AnaBios and Sanofi Enter into Agreement 63
Iontas Enters into Agreement with Sanofi 64
Alnylam Pharma and Sanofi to Enter into Agreement 65
Sanofi to Form Partnership with Groupe Saidal and Pasteur Institute of Algeria 66
Berg Enters into Research Agreement with Sanofi 67
Applied BioMath Enters into Partnership with Sanofi 68
Sanofi Enters into Agreement with Max Delbruck Center, Charite and Berlin Institute of Health 69
Thermalin Enters into Partnership with Sanofi 70
Bioverativ Enters into Research Agreement with Bicycle Therapeutics 71
Axxam Enters into Research Agreement with Sanofi 72
AbCellera Biologics Enters into Partnership with Sanofi Pasteur 73
Ex Scientia Enters into Research and Option Agreement with Sanofi 74
Sanofi Enters into Research Agreement with Exscientia 75
Sanofi Enters into Co-Development Agreement with MedImmune 76
Sanofi Enters into Co-Promotion Agreement with Yakult Honsha 77
Enteris BioPharma Enters into Agreement with Sanofi 78
Sanofi Enters into Agreement with JHL Biotech 79
Natrix Separations Enters into Co-Development Agreement with Merck and Sanofi 80
Mymetics Enters into Research Agreement with Sanofi 81
Alnylam Pharma Enters into Agreement with Sanofi Genzyme 82
Myriad Enters into Agreement with Sanofi 83
Sanofi Pasteur Enters into Contract with US Department of Health and Human Services 84
Sanofi Pasteur Expands R&D Agreement with Walter Reed Army Institute of Research and Bio Manguinhos and Fiocruz 85
Sanofi Enters into Co-Development Agreement with Joslin Diabetes Center 86
Sanofi Enters into Research Agreement with Ksilink 87
Sanofi Genzyme Enters into Research Agreement with Johns Hopkins School of Medicine 88
Recursion Pharma Enters into Research Agreement with Genzyme 89
Hummingbird Bioscience Enters into Partnership with Sanofi 90
Sanofi Enters into Research Agreement with DiCE Molecules 91
Sanofi Enters into Drug Discovery Agreement with University of Tokyo 92
Sanofi and Juvenile Diabetes Research Foundation Partner with Four Research Organizations 93
Jubilant Biosys Enters into Agreement with Sanofi-Aventis Deutschland 95
X-Chem Enters into Agreement with Sanofi 96
Daiichi Sankyo, Japan Vaccine and Sanofi Enter into Co-Marketing Agreement 97
Sanofi Pasteur Enters into Partnership with Infectious Disease Research Institute 98
PeptiDream Enters into Discovery Agreement with Sanofi 99
Evotec Enters into Research Agreement with Sanofi 100
Regeneron Pharma Amends Co-Development Agreement with Sanofi 101
Sanofi-Aventis Extends Agreement with Medicines For Malaria Venture 103
Zhejiang Hisun Pharma Enters into Memorandum of Understanding (MoU) with Sanofi 104
Pendopharm Enters into Distribution Agreement with Sanofi-aventis Canada 105
NeuroVive Pharma Enters into Co-Development Agreement with Sanofi 106
Ablynx Enters into Research Agreement with Genzyme 107
Innate Pharma Enters into Agreement with Sanofi for Next Generation Antibody-Drug Conjugates 108
VBI Vaccines Enters into Research Agreement with Sanofi Pasteur 109
Schrodinger Enters into Agreement with Sanofi 110
Regeneron Pharma Amends Co-Development Agreement with Sanofi 111
Voyager Therapeutics Enters into Development Agreement with Genzyme 112
Adimab Enters into Agreement with Sanofi for Bispecific Antibody 113
Sanofi Enters into Research Agreement with Vect-Horus 114
Catalent Pharma Enters into Co-Development Agreement with Sanofi-Aventis 115
Evotec to Enter into Co-Development Agreement with Sanofi 116
Immune Design Enters into Co-Development Agreement with Sanofi Pasteur 118
Selecta Biosciences and Juvenile Diabetes Research Foundation Enter into Co-Development Agreement with Sanofi 119
Apollo Hospitals Plans to Form Joint Venture with Sanofi 120
Genzyme Enters into Co-Development Agreement with University of Florida and University of Pennsylvania 121
Charcot-Marie-Tooth Association Enters into Agreement with Genzyme to Discover Therapies for CMT1A 122
Sanofi Extends its Co-Development Agreement with MyoKardia 123
Sanofi Enters into Distribution Agreement with Emcure for Oncology Drugs 125
Sanofi Enters into Co-Development Agreement with Medtronic 126
Sanofi Enters into Drug Discovery Agreement with CQDM 127
Dubai Investments to Enter into Agreement with Sanofi to Promote Generics 128
Genzyme Enters Into Research Agreement With Cleveland Clinic 129
Sanofi Pasteur Enters Into Agreement With SK Chemicals For Pneumococcal Conjugate Vaccine 130
Sanofi Enters Into Agreement With UCB For Drug Discovery 131
Alnylam Pharma And Genzyme Enter Into Agreement For RNAi Therapeutics As Genetic Medicines 132
Smartox Biotech Enters Into Research Agreement With Sanofi For Drug Discovery 134
Regulus Therapeutics Expands Agreement With Sanofi 135
Sanofi Pasteur Enters into Agreement with University of Melbourne to Develop Human Vaccines 137
Alnylam Pharma And Genzyme Expands Co-Development Agreement For RNAi Therapeutics 138
Sanofi Pasteur Enters Into Agreement With Bill & Melinda Gates Foundation To Discover Vaccines 139
Gubra Enters into Research Collaboration with Sanofi 140
Institut Curie Enters Into Research Agreement With Sanofi To Develop Ovarian Cancer Treatments 141
NextBio Enters Into Agreement With Sanofi For Translational Medicine 142
Takeda Pharma Enters Into Co-Promotion Agreement With Sanofi For Alogliptin 143
Sanofi Pasteur Enters Into Co-Development Agreement With Xiamen University For Universal Flu Vaccine 144
Oncodesign Enters Into Research Agreement With Sanofi 145
Sanofi-Aventis Expands Co-Promotion Agreement with NovaMed Pharma 146
PharmAbcine Enters Into Research Agreement With Sanofi For Antibody Drug Discovery 147
Sutro Biopharma Enters Into Co-Development Agreement With Sanofi Pasteur 148
Y-Biologics Expands Agreement with Sanofi 149
Hanmi Pharma Enters Into Co-Marketing Agreement With Sanofi-Aventis For Ibestin 150
LG Life Sciences Enters Into Co-Promotion Agreement With Sanofi-Aventis Korea For Zemiglo 151
Sanofi Enters Into R&D Agreement With Massachusetts General Hospital For Translational Oncology Research 152
China State Institute of Pharma Enters Into Research Agreement With Sanofi 153
Sanofi Enters Into Research Agreement With Charite- Universitatsmedizin For Treatment Of Diabetes 154
Sanofi Enters Into Research Agreement With TB Alliance To Advance Treatments For Tuberculosis 155
Sanofi Enters Into Research Agreement With Oncodesign 156
LegoChem Biosciences Enters into Research Agreement with Sanofi 157
Sanofi Enters Into Research Agreement With Brigham and Womens Hospital 158
Regulus Therapeutics Expands Agreement With Sanofi-Aventis 159
Sanofi Forms Joint Venture With Hisamitsu Pharma For OTC Medications 160
Sanofi Enters Into Co-Development Agreement With Joslin Diabetes Center For Novel Diabetes Drugs 161
Sanofi Enters Into Research Agreement With Bioneer 162
Sanofi Enters Into Co-Development Agreement With Alfresa For Antiepileptic Drug 163
Sanofi Enters into Co-Development Agreement with CNRH, INRA, ASL and 3iNature 164
Centre For Genomic Regulation Enters Into Research Agreement With Sanofi 165
Centre de Regulacio Genomica Enters Into Research Agreement With Sanofi 166
Sanofi Pasteur India Enters Into Co-Marketing Agreement With Emcure Pharma For Rabies Vaccine 167
University of California Enters Into Research Agreement With Sanofi 168
Foundation Medicine Enters Into Co-Development Agreement With Sanofi For Genetic Biomarkers And Potential Diagnostics 169
Sanofi Japan and Genzyme Japan Merge 170
Bioverativ Enters into Licensing Agreement with Oxford BioMedica 171
Sanofi Pasteur Enters into Licensing Agreement with SK Chemicals 172
Asahi Kasei Pharma Enters into Licensing Agreement with Sanofi 173
Sanofi to Enter into Licensing Agreement with Principia Biopharma 174
Sanofi Enters into Licensing Agreement with Ablynx 175
Sanofi Enters into Licensing Agreement with ImmuNext 176
Sanofi Enters into Licensing Agreement with Hanmi Pharma 177
IXALTIS Enters into Licensing Agreement with Sanofi 178
Mundipharma Enters into Licensing Agreement with SkyePharma and Sanofi for Flutiform 179
Sanofi Enters into Licensing Agreement with Innate Pharma 180
Sanofi Amends Licensing Agreement with Lexicon Pharma 181
Sanofi Enters into Licensing Agreement with Ligand Pharma 183
Zai Lab Enters into Licensing Agreement with Sanofi 184
Sanofi Enters into Licensing Agreement with Immune Design 185
CureVac Enters into Licensing Agreement with Sanofi Pasteur to Develop mRNA-Based Prophylactic Vaccine 186
Sanofi Enters into Licensing Agreement with Eli Lilly for Cialis 187
Oxford BioMedica Amends Licensing Agreement With Sanofi 189
Regulus Therapeutics Amends Licensing Agreement With Sanofi 190
Tolero Pharma Enters Into Licensing Agreement With Sanofi For Alvocidib 191
Chugai Pharma Expands Licensing Agreement with Kowa for DEBERZA 192
Sanofi Enters into Licensing Agreement with Bristol-Myers Squibb 193
Lumena Pharma Enters Into License Agreement With Sanofi For LUM002 194
Sanofi Pasteur Expands Licensing Agreement With Vivalis 195
Sanofi Enters into Licensing Agreement with Affilogic 196
Sanofi Enters into Licensing Agreement with Warp Drive Bio 197
Sanofi Enters into Licensing Agreement with MAB Discovery 198
Sanofi Enters into Licensing Agreement with BioNTech 199
Selecta Biosciences Exercises Option for Licensing Agreement with Sanofi 200
Sanofi Enters into Licensing Agreement with Lead Pharma for Autoimmune Diseases 201
ZAI Lab Enters into Licensing Agreement with Sanofi for Two Respiratory Drugs 202
Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Intra-Strand Base-Pairing Technology 203
Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Duplex Gene Therapy Vector Technology 204
Sanofi Pasteur Enters Into Licensing Agreement With ORGANOBALANCE For Saccharomyces Cerevisiae 205
JHL Biotech Raises USD80 Million in Private Placement of Shares 206
Voyager Therapeutics Raises USD30 million in Private Placement of Series B Preferred Stock 207
Alnylam Pharma Raises USD70.7 Million in Private Placement of Shares 208
X4 Pharma Spin Off from Sanofi 210
Regulus Therapeutics Completes Private Placement Of Shares For US$10 Million 211
KaloBios Pharma Completes IPO For US$70 Million 212
Sanofi Prices Third Tranche of Public Offering of 0.5% Notes Due 2023 for USD2.2 Billion 214
Sanofi Prices Second Tranche of Public Offering of Notes Due 2020 for USD0.6 Billion 215
Sanofi Prices Fourth Tranche of Public Offering of 1% Notes Due 2026 for USD1.9 Billion 216
Sanofi Prices Fifth Tranche of Public Offering of 1.375% Notes Due 2030 for USD2.47 Billion 217
Sanofi Prices Sixth Tranche of Public Offering of 1.875% Notes Due 2038 for USD1.6 Billion 218
Sanofi Prices First Tranche of Public Offering of Notes Due 2020 for USD1.2 Billion 219
Sanofi Prices Public Offering of Notes Due 2022 for USD948 Million 220
Sanofi Prices Public Offering of Notes Due 2027 for USD1.3 Billion 221
Sanofi Prices Public Offering of Notes Due 2020 for USD1.1 Billion 222
Sanofi Raises USD798.08 million in Public Offering of Notes Due 2028 223
Sanofi Raises USD684.07 million in Public Offering of Notes Due 2024 224
Sanofi Raises USD570 million in Public Offering of Notes Due 2019 225
Sanofi Prices Public Offering of Notes Due 2019 for USD850 Million 226
Sanofi Prices Public Offering of 1.5% Notes Due 2025 for USD850 Million 227
Sanofi Prices Public Offering of 0.875% Notes Due 2021 for USD566.4 Million 228
Sanofi Prices Public Offering of 1.75% Notes Due 2026 for USD1.64 Billion 229
Sanofi Prices Public Offering of 1.125% Notes Due 2022 for USD1.31 Billion 230
Sanofi Prices Public Offering of Floating Rate Notes Due 2018 for USD984 Million 231
Sanofi Prices Public Offering Of Bonds Due 2023 For US$1.35 Billion 232
Sanofi Prices Public Offering Of Bonds Due 2020 For US$1.3 Billion 233
Sanofi Completes Public Offering Of Notes Due 2018 For US$1.5 Billion 234
Sanofi Completes Public Offering Of Notes Due 2017 For US$960 Million 236
Partner Therapeutics Acquires Rights of Leukine from Sanofi 237
MicroPharm Acquires Equine Antivenom Immunoglobulin Products from Sanofi Pasteur 238
Emergent BioSolutions Acquires ACAM2000 Business from Sanofi 239
INTEGA Skin Sciences Acquires Alyria Skincare Product Line from Sanofi Consumer Health for USD1.3 Million 241
Ipsen Acquires Healthcare Portfolio from Sanofi for USD88.3 Million 242
Impact Biomedicines Acquires Rights for Fedratinib from Sanofi 244
Icagen Acquires Arizona Research Facility from Sanofi 245
Merus Labs Acquires French Rights to Four Products from Sanofi for USD25 Million 246
Validus Pharma and Wood Creek Capital Acquire US Rights to Several Product Lines from Sanofi-Aventis US 247
Moberg Pharma Acquires Balmex from Chattem for USD3.9 Million 248
Valeant Canada Acquires Canadian Rights from Sanofi-aventis for Altace and Altace HCT 249
Ferring Pharma Acquires Ddavp from Sanofi 250
Prollenium Medical Acquires Rights to Alyria Skincare Portfolio from Sanofi Consumer Health 251
Admedus Acquires Manufacturing Facility From Genzyme Australasia 252
Regeneron Pharma Acquires Rights To Two Antibodies From Sanofi 253
Covis Pharma To Acquire US Commercialization Rights For Five Products From sanofi-aventis 254
Wood Pharma To Acquire Production Facility In Hlohovec From Zentiva 256
Fareva Acquires API Production Site from Sanofi 257
Ubichem Pharma Services Acquires Manufacturing Facility In Hungary From Sanofi 258
Sanofi Acquires Bioverativ for USD11.5 Billion in Tender Offer 259
Zentiva to Acquire Additional 18.32% Stake in Sicomed for USD70.9 Million 261
Sanofi to Acquire Ablynx for USD4.85 Billion 262
Sanofi Acquires Protein Sciences 264
Bioverativ Therapeutics Acquires True North Therapeutics 265
Eurapharma Plans to Acquire 51% Stake in Maphar 266
Medis Labs Acquires Winthrop Pharma from Sanofi 267
Sanofi May Acquire Flexion Therapeutics for up to USD1 Billion 268
Sanofi May Acquire BioMarin Pharma 269
Sanofi to Sell 4.76% Stake in Nichi-iko Pharma 270
Sanofi May Acquire PTC Therapeutics 271
Sanofi-Synthelabo Acquires 20% Stake in Apollo Sugar Clinics for USD14.6 Million 272
Dubai Investments Divests 66% Stake in Globalpharma 273
Aastrom Biosciences Completes Acquisition of Genzyme Biosurgery from Sanofi for USD6.5 Million 274
Sanofi-Aventis To Acquire Minority Stake In Shantha Biotechnics For US$123 Million 275
LOreal Plans To Sell Its Stake In Sanofi 276
Sanofi Plans To Acquire Consumer Healthcare Products Company In China 277
Sanofi Completes Acquisition Of Genfar, Generic Drugs Manufacturer 278
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 279
Sanofi-Aventis Israel To Acquire Consumer Healthcare Products Company 281
Evotec Acquires DeveloGen For USD18 Million 282
Sanofi, Key Competitors 284
Sanofi, Key Employees 285
Sanofi, Subsidiaries 287
Sanofi, Joint Venture 300

List Of Figures

List of Figures
Sanofi, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sanofi, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sanofi, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sanofi, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sanofi, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 14
Sanofi, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 15
Sanofi, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 16
Sanofi, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 17
Sanofi, Medical Devices Deals, 2012 to YTD 2018 19

Sanofi (SAN) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Sanofi is a healthcare company that researches, develops, manufactures and markets a wide range of medicines and vaccines. Its product portfolio includes medicines for the treatment of cancer, diabetes, rare

USD 250View Report

Sanofi Genzyme - Mergers and Acquisitions (M&A), Partnerships and Alliances and Investment Report

Sanofi Genzyme - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportMarketlines Sanofi Genzyme Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports

USD 350View Report

Sanofi (SAN) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Sanofi is a healthcare company that researches, develops, manufactures and markets a wide range of medicines and vaccines. Its product portfolio includes medicines for the treatment of cancer, diabetes, rare

USD 250View Report

Sanofi (SAN) - Strategic SWOT Analysis Review

Sanofi (SAN) - Strategic SWOT Analysis Review provides a comprehensive insight into the companys history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on

USD 125View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 250
  • Site Licence    USD 500
  • Enterprise Wide Licence    USD 750
$ 250

Reports Details

Published Date : Apr 2018
No. of Pages :358
Country :France
Category :Pharmaceuticals and Healthcare
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube